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ABSTRACT
The toxicity and efficacy of dapsone given daily as Pneumocystis jiroveci (PCP) prophylaxis in hematopoietic
stem cell transplant (HSCT) recipients who cannot take trimethoprim-sulfamethoxazole (TMP-SMX) have
not been fully evaluated. We compared 155 HSCT recipients who received daily dapsone as second-line PCP
prophylaxis with 310 matched control patients who received TMP-SMX throughout the posttransplantation
course. Among patients who started dapsone before transplantation because of TMP-SMX allergy, there was
no difference in the transfusion requirement after HSCT when compared with controls. Among patients who
started dapsone after transplantation, increased red blood cell (P < .0001) and platelet transfusion (P  .003)
requirements were noted compared with controls. This effect was, however, limited to patients who were
receiving dapsone for reasons (mostly neutropenia) other than TMP-SMX allergy. Two of 155 patients
developed PCP, compared with 0 of 310 controls (P  .11); both patients survived. In conclusion, the efficacy
of daily dapsone in preventing PCP was similar to that observed in patients able to remain on TMP-SMX
prophylaxis. Dapsone did not seem to cause hematologic toxicity among TMP-SMX–allergic patients. The
observed higher transfusion need in patients who received dapsone for reasons other than TMP-SMX allergy
seems mostly due to an underlying condition of poor marrow reserve. Further studies are required to establish
whether the drug has an etiologic role in these situations.
© 2005 American Society for Blood and Marrow Transplantation
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Pneumocystis jiroveci (formerly carinii) pneumonia
PCP) is a serious and potentially life-threatening in-
ection that can occur in an immunocompromised
ost and is one of the major concerns in patients who
ndergo hematopoietic stem cell transplantation
HSCT) [1-4]. However, prevention of PCP is also
ne of the greatest successes in the ﬁeld of infection
rophylaxis after HSCT. Indeed, its incidence was
educed from 8%-15% to 0.2% after the introduction
f trimethoprim-sulfamethoxazole (TMP-SMX) as a
rophylactic agent [5,6]. In addition, whereas in past
ecades this infection occurred mostly 40 to 80 days
B&MTfter transplantation, it is now rare and principally
ccurs after 6 months after transplantation [7]. Main
isk factors are extensive chronic graft-versus-host dis-
ase (GVHD), ongoing corticosteroid use, and relapse
f malignant disease [8].
The need for an alternative prophylactic agent
anges from 17% to 38%. The main reasons are in-
olerance/allergy and neutropenia [9,10]. There seems
o be an increased need for alternative agents because
f the increased use of drugs that may cause cumula-
ive toxicities with TMP-SMX, such as ganciclovir or
alganciclovir, mycophenolate mofetil, and imatinib.Aerosolized pentamidine, dapsone, and, recently,
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5tovaquone [11] are the possible candidates for sec-
nd-line therapy. In both human immunodeﬁciency
irus (HIV)–infected individuals and HSCT recipi-
nts, aerosolized pentamidine has been associated with
ess protection than TMP-SMX [12-14]. Some stud-
es, however, still suggest aerosolized pentamidine as a
alid prophylactic agent in immunodeﬁciency [15-17]
nd post-HSCT settings [18-20]. A small study in
ediatric marrow transplant recipients reported dap-
one (50 mg/m2 once a week) as a valid and well-
olerated agent for pediatric patients intolerant of
MP-SMX [21]. In a retrospective study conducted at
ur center, intermittent administration of dapsone (50
g orally twice daily 3 times per week) as second-line
rophylaxis was associated with high rates of break-
hrough PCP after HSCT. The failure rate was 7.2%,
ith an associated relative risk for PCP of 18.8 (P 
01) [10]. On the basis of this result, daily dosing was
dvocated [10]. The recommendation was supported
y a randomized study conducted in HIV-infected
ubjects [22]. However, few data exist on the toxicity
f daily dapsone used as second-line prophylaxis after
SCT. Vasconcelles et al. [13], in a retrospective
ohort study, conﬁrmed that TMP-SMX is superior
o aerosolized pentamidine as primary prophylaxis af-
er HSCT and also showed that a limited group of 31
atients treated with daily dapsone (100 mg/d) did not
ave a signiﬁcantly increased probability of PCP or
eath compared with those treated with TMP-SMX.
he toxicity rate was higher than that with standard
reatment, and hemolytic reactions were the greatest
oncern. Additional dapsone side effects include intol-
rance/allergy, methemoglobinemia, gastrointestinal
dverse events, and myelosuppression [13]. The dap-
one hydroxylamine metabolite is considered to be
esponsible for the hemolytic effects; it leads to a loss
f erythrocytic glutathione content [23,24]. Screening
atients for glucose-6-phosphate dehydrogenase
G6PD) deﬁciency is advised before the drug is started
25] and could help prevent hemolytic reactions. The
linical relevance of hemolytic anemia has been poorly
valuated. Indeed, no data are available on the trans-
usion requirements after dapsone administration.
We conducted a retrospective case-control study
o evaluate the toxicity and efﬁcacy of daily dapsone
50 mg twice daily) as second-line PCP prophylaxis in
atients undergoing HSCT. We investigated the clin-
cal relevance of hematologic toxicity, especially in
erms of transfusion requirements, and the incidence
f PCP and other relevant infections.
ETHODS
atients
We conducted a retrospective matched control
tudy on 155 patients who underwent HSCT at the e
22red Hutchinson Cancer Research Center (FHCRC;
eattle, WA) between 1998 and 2001 and who re-
eived daily dapsone as PCP prophylaxis for more
han 1 week by day 100 after transplantation. Pa-
ients who were already discharged from the FHCRC
r those who had experienced leukemic relapse before
tarting their prophylaxis were excluded. Dapsone re-
ipients (cases) were divided into 2 groups according
o whether prophylaxis with dapsone was given for the
rst time before or after HSCT.
Each case was matched with 2 control patients
ho received standard TMP-SMX prophylaxis.
atching criteria were the type of HSCT (autologous
r syngeneic; allogeneic/myeloablative versus alloge-
eic/nonmyeloablative) and donor type (related versus
nrelated). The transplantation date in control pa-
ients was as close as possible to that of their corre-
ponding cases.
Control patients also had to be alive and free from
eukemic relapse at least as long as the start date of
apsone in their corresponding cases. The study was
pproved by the FHCRC Institutional Review Board.
rophylaxis Regimen
PCP prophylaxis was given according to FHCRC
nternal clinical practice guidelines. The recom-
ended standard treatment with TMP-SMX started
n the pretransplantation period, upon admission for
SCT, with 1 double-strength tablet (800 mg of
ulfamethoxazole and 160 mg of trimethoprim) twice
aily orally, was discontinued 48 hours before trans-
lantation, and was generally reintroduced in the
osttransplantation period when the absolute neutro-
hil count (ANC) is 500/mm3 for 3 days. Patients
ho were allergic to TMP-SMX were generally re-
erred to desensitization [10].
If TMP-SMX could not be administered by day
30 or if desensitization failed, the use of alternative
rophylaxis was recommended, and dapsone (50 mg
rally twice daily) was considered the second-line
reatment. The dose was divided into 2 daily admin-
strations to avoid a high peak serum level that may
orrelate with hematologic toxicities (median day
17). For pediatric patients, the dose was adjusted to
mg/kg/d in 2 divided doses (up to 100 mg/d). When
tarted before HSCT, upon admission for HSCT
based on unpublished results by the manufacturer),
apsone was recommended to be discontinued 2 days
efore stem cell infusion and during the initial trans-
lantation period, as was done for TMP-SMX. Pro-
hylaxis with dapsone was not given if G6PD deﬁ-
iency was found in the recipient [25].
Both standard and second-line prophylaxis were
ontinued for at least 6 months after transplantation
r for as long as patients had evidence of clinical
xtensive chronic GVHD or continued to receive sys-
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Dapsone for PCP Prophylaxis
Bemic immunosuppressive therapy. Patients receiving
apsone were also prescribed penicillin VK (750 mg
wice daily).
oxicity
Red blood cell (RBC) and platelet transfusion re-
uirements were evaluated after medication for pa-
ients who had dapsone only in the posttransplanta-
ion period and after HSCT for patients who started
heir dapsone prophylaxis before HSCT. Patient clin-
cal and laboratory data were collected until discharge
ate, death, relapse, or subsequent transplantation.
ransfusion requirements were expressed as units re-
uired per 100 days of follow-up (time from HSCT or
apsone start to the earliest of the above-mentioned
nd points). The results were stratiﬁed into 2 groups
ccording to the reason for starting dapsone (allergy/
ntolerance to TMP-SMX versus other reasons). Re-
ults were adjusted for other factors potentially asso-
iated with transfusion requirements, such as major
BO mismatch and severe GVHD (grade III or IV).
ll cases and controls were well balanced with respect
o stem cell source (bone marrow versus peripheral
lood stem cells). The cumulative incidence for liver
aspartate aminotransferase and alanine aminotrans-
erase 200 IU/L and bilirubin 2 mg/dL), renal
creatinine 1.5 mg/dL), or hematologic (haptoglo-
in 100 mg/dL, hemoglobin 8 g/dL, hematocrit
24%, and lactate dehydrogenase 400 IU/L) toxic-
ty after medication was evaluated only in patients who
eceived dapsone for the ﬁrst time in the post-HSCT
etting . Toxicity data were analyzed until death, dis-
harge, relapse, subsequent transplantation, or day
100 after HSCT, whichever came earlier, and were
djusted for age, severe GVHD, major ABO mis-
atch, and stem cell source. Summaries from clinical
ecords were reviewed to identify episodes of intoler-
nce or toxicity leading to the drug suspension.
fficacy
Efﬁcacy was evaluated by the incidence of PCP in
he 2 groups at any time after HSCT. The incidence
f PCP was also evaluated in the entire transplant
opulation during the study period. Infection data
fter discharge from Seattle were obtained by using
he long-term follow-up database. This database in-
ludes results from annual surveys on symptoms and
omplications, transcripts of telephone consultations,
opies of clinic notes, hospital admission and dis-
harge reports, and death reports. Diagnoses of PCP
ere accepted only if clinical records documented
CP in clinical specimens. Incidence ﬁgures for inva-
ive pneumococcal pneumonia infection, nocardiosis,
oxoplasmosis, and Haemophilus inﬂuenzae and parain-
uenzae infections at any time after HSCT were also
ollected. s
B&MTtatistical Analysis
Descriptive statistics such as median, 25th and
5th percentiles, and range were calculated as appro-
riate. Transfusion requirements were adjusted for
ays of follow-up. Adjusted transfusion requirements
ere compared between groups by the Wilcoxon
-sample test. The analysis was stratiﬁed according to
he reason for starting dapsone (TMP-SMX allergy
ersus other reasons). Analysis of variance on ranked
djusted transfusion values was used to adjust for ma-
or ABO mismatch, GVHD, and other possible con-
ounders. Cumulative incidence curves for toxicity
easures were plotted by using methods previously
escribed [26]. Statistical comparisons of the toxicity
easures between groups were based on likelihood
atio statistics from Cox proportional hazard models,
hich included adjustment for possible confounding
actors. The rates of PCP and other infections were
ompared between groups by Fisher exact test. All P
alues are 2 sided.
ESULTS
One hundred seventy-three patients were identi-
ed who received daily dapsone before day100 after
ransplantation (Table 1). Thirteen patients who re-
eived dapsone after HSCT for less than 1 week were
xcluded. These patients were switched back to
tandard therapy after transient neutropenia, toxic-
ty, or TMP-SMX desensitization (n  7), if they
xperienced intolerance or toxicity associated with
apsone (n  3), or without a clear reason noted in
he chart (n  3). Three patients who were dis-
harged from the FHCRC, and 2 who experienced
eukemic relapse before prophylaxis started were ex-
luded. A ﬁnal number of 155 cases were evaluated for
he study and compared with a group of 310 controls.
aseline characteristics are shown in Table 1. Overall,
pproximately 10% (155 of 1512 patients who under-
ent transplantation) of patients received dapsone
uring the ﬁrst 3 months after transplantation.
Cases and controls were well matched (Table 1).
owever, patients who started dapsone after trans-
lantation had a lower ANC and platelet count than
ontrols receiving TMP-SMX. When stratiﬁed by the
eason for dapsone administration, no difference was
pparent in those in whom dapsone was given for
MP-SMX allergy (Table 1), thus suggesting that the
ifference was driven by those in whom dapsone was
iven for an underlying poor marrow reserve.
The median overall follow-up (time from prophy-
axis start to date of last contact) was 29 months for
ases (range, 0.3-72.6 months) and 28.9 for controls
range, 0.1-65.5 months). Allergy to TMP-SMX and
ituations of depressed marrow function were the
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524ost frequently reported reasons for alternative PCP
rophylaxis (Table 2).
oxicity
A higher probability of a decrease in hemoglobin
evel (8 g/dL) after medication was observed for
atients who received dapsone for the ﬁrst time in the
osttransplantation setting compared with controls
adjusted P .02). After a stratiﬁed analysis, the result
as no longer signiﬁcant for patients allergic to TMP-
MX (P  .54; Figure 1). No signiﬁcant differences
ere observed for liver enzymes (aspartate amino-
ransferase or alanine aminotransferase), serum creat-
nine, lactate dehydrogenase, haptoglobin, or hemat-
crit abnormalities (data not shown).
Clinical adverse effects with dapsone use were
eported in 19 (12%) of 155 cases and included intol-
rance or allergy (n  5), hemolysis (n  9), and
emolysis with methemoglobinemia (n  5). This led
o discontinuation or temporary suspension of dap-
one in 16 cases (10%). None of these episodes was
escribed as life threatening. Eleven of the hemolytic
vents induced the clinician to suspend dapsone, re-
ulting in a resolution or improvement in 8 cases; 3
atients did not have a clear beneﬁcial effect after drug
emoval. Hemolysis did not require dapsone suspen-
ion in 3 episodes, either because they were thought to
e mostly due to ABO mismatch (n  2) or because
hey were deﬁned as mild and resolved when TMP-
MX was reintroduced after a temporary condition of
epressed marrow function. A G6PD deﬁciency is
nlikely to be the reason for the reported hemolytic
pisodes because, according to our guidelines, all pa-
ients had a normal G6PD value before they started
apsone.
ransfusion Requirement
Among the 116 patients who started dapsone after
SCT (median, day 51; range, 16-91 days), there
as a higher RBC and platelet transfusion require-
ent compared with controls. Results were adjusted
or major ABO mismatch and severe GVHD (Table
). After stratifying the analysis according to the rea-
on why second-line PCP prophylaxis was required
TMP-SMX allergy versus no allergy), we observed
apsone Start after HSCT (n  116) Total Cases (n  155)
48 (41%) 83 (54%)
47 (41%) 47 (30%)
6 (5%) 6 (4%)
5 (4%) 5 (3%)
10 (9%) 14 (9%)
for the ﬁrst time before transplantation (after admission) or in the
P-SMX poor marrow function was the main reason for secondaryable 1. Baseline Characteristics of All Patients, Acute GVHD
ncidence, and Engraftment Data
Variable
Dapsone
(n  155)
Controls
(n  310)
ge at transplantation, y,
median (range) 44 (1–70) 44 (1–68)
ex
Male 62 (40%) 165 (53%)
Female 93 (60%) 145 (47%)
ace
Caucasian 133 (86%) 254 (82%)
Other 22 (14%) 56 (18%)
ain diagnosis
Hematologic malignancy 138 (89%) 270 (87%)
Other 17 (11%) 40 (13%)
tem cell source
BM 63 (41%) 127 (41%)
PBSC 90 (58%) 175 (56%)
BM  PBSC 0 (0%) 3 (1%)
Cord blood 2 (1%) 5 (2%)
onor type
Autologous/identical twin 31 (20%) 63 (20%)
Related 60 (39%) 117 (38%)
Unrelated 64 (41%) 130 (42%)
onditioning regimen
Myeloablative 139 (90%) 279 (90%)
Nonmyeloablative 16 (10%) 31 (10%)
BO mismatch (6 unknown)
Matched 120 (80%) 251 (81%)
Mismatched 30 (20%) 58 (19%)
cute GVHD*
Grade 0–II 92 (74%) 187 (77%)
Grade III/IV 32 (26%) 57 (23%)
ut GVHD1
Grade III 3 (2%) 11 (5%)
Grade IV 3 (2%) 11 (5%)
NC (109/L) at dapsone start,
median (range)†
No TMP-SMX allergy 1.9 (0–16.5)‡ 3.6 (0–20.9)‡
TMP-SMX allergy 3.4 (0.3–11.2) 3.8 (0–18.7)
LT (109/L) at dapsone start,
median (range)†
No allergy 49 (4–232)‡ 104 (16–366)‡
Allergy 80 (14–275) 87 (7–383)
M indicates bone marrow; PBSC, peripheral blood stem cells;
PLT, platelets.
Excluding autologous and syngeneic donor (and ungraded).
Among those starting dapsone after transplantation.able 2. Reasons for Use of Dapsone as Secondary PCP Prophylaxis
Reason for Dapsone Dapsone Start before HSCT (n  39) D
MP-SMX allergy 35 (90%)
oor marrow function 0
iver toxicity 0
enal toxicity 0
ot reported 4 (10%)
esults are divided into 2 groups according to whether dapsone was started
posttransplantation period. Among patients who were not allergic to TM
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Bhat a higher need for RBC and platelet transfusions
as limited to patients who received dapsone for rea-
ons other than TMP-SMX allergy, mostly poor graft
unction or hematologic toxicity associated with
MP-SMX (Table 3). This group of patients had a
igher need for transfusion support than controls,
ven before the prophylaxis started, and this suggests
poor graft function at the start of drug. The medians
or 100 days of RBC and platelet transfusion units
ere in fact 10.5 and 11.5 versus 0 in the control
roup (P .003 and P .005, respectively). ANC and
latelet counts at the time of prophylaxis start were
lso signiﬁcantly lower (P  .0001) compared with
ontrols (Table 1). Patients whose reason for dapsone
as an allergy or intolerance to TMP-SMX had a
ransfusion requirement similar to that of controls
Table 3). The distribution of RBC and platelet trans-
usions among patients who started their second-line
rophylaxis after HSCT is shown in Figure 2. The
roup of 39 patients who started their dapsone before
SCT did not have a signiﬁcant difference in RBC or
latelet requirements after transplantation compared
ith controls. Their medians for RBC and platelet
ransfusion units per 100 days of follow-up were 12
nd 41, versus 12.5 and 65.5 among controls (P  .67
igure 1. Distribution of red blood cell (A and B) and platelet (pane
fter HSCT (n  116) and their corresponding controls (n  232)
rouped according to the reason for dapsone secondary prophylaxind P  .26, respectively). Thirty-ﬁve of these pa- I
B&MTients were found to be allergic to TMP-SMX, and in
cases the reason for dapsone was not clearly reported
Table 2).
fficacy
Two of 155 cases (1.3%; 95% conﬁdence interval,
.35%-4.6%) were diagnosed with PCP, whereas
one of the 310 controls (0%; 95% conﬁdence inter-
al, 0%-1.2%) developed the infection. The differ-
nce was not statistically signiﬁcant (P .11; Table 4).
hen all patients who received TMP-SMX during
he study period were analyzed, the incidence was 5
0.37%; 95% conﬁdence interval 0.16% to 0.86%) of
357.When compared with the dapsone group, this also
id not reach statistical signiﬁcance (P  .16). Both
atients who developed PCP after dapsone received a
onmyeloablative conditioning regimen; the ﬁrst was
rom a related donor after an autologous graft (2
onths earlier) as treatment for a multiple myeloma,
nd the second was from an unrelated donor for non-
odgkin lymphoma that relapsed 3 years after a pre-
ious autologous transplantation. The PCP diagnoses
ere made at 7.5 and 11 months after HSCT. At that
ime, both patients were taking dapsone as prescribed.
d D) transfusions for patients who started dapsone for the ﬁrst time
lts are expressed as number of units/100 days of follow-up and are
-SMX allergy versus no allergy).ls C an
. Resummunosuppressive therapy included corticosteroids
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5nd cyclosporin A in both patients. The ﬁrst had a
iagnosis of stable chronic GVHD and a partial graft
ailure with persistent partial (50%) donor T-cell en-
raftment; the second had a recent increase of the
yclosporin A dose after initial tapering because of
VHD development. Both patients responded to
reatment with intravenous pentamidine.
Among the cases receiving dapsone that were re-
iewed for this study, we found 1 patient with a pneu-
ocystis lung granuloma during the pretransplanta-
ion evaluation while not receiving any speciﬁc
rophylaxis. Among controls, there was also 1 patient
ith PCP approximately 2 months before transplan-
ation, before the prophylactic regimen with TMP-
MX started. Neither patient had any recurrence of
CP after transplantation.
The incidence of infections with encapsulated mi-
roorganisms or nocardia species seemed higher
mong patients who required dapsone (n  12) pro-
hylaxis when compared with controls (n  9; P 
03; Table 4). However, by the time that the infectious
vent occurred (cases: median, 8.5 months; range,
-55 months after HSCT; controls: median, 6
onths; range, 2-31 months after HSCT), only 6 of
hese 12 cases were still taking an alternative PCP
rophylaxis that did not consist of TMP-SMX (2
apsone and 4 pentamidine). Five of the remaining
atients were switched back to TMP-SMX, whereas 1
ad the infection before the second-line prophylaxis
tarted.
No information was available regarding whether
enicillin or other drugs for encapsulated bacteria
ere administered. Among those who restarted TMP-
able 3. Transfusion Requirement Expressed in Number of Un
fter Transplantation
Variable
Red Blood
Dapsone Contro
ll patients
n 116 232
Median units/100 d 10.0 0.0
Q1-Q3‡ 0-20 0-11
Range 0-190 0-12
apsone for TMP-SMX allergy
n 48 96
Median units/100 d 4.0 3.5
Q1-Q3‡ 0-15 0-13
Range 0-43 0-10
apsone for reasons other than
TMP-SMX allergy
n 68 136
Median units/100 d 12.0 0.0
Q1-Q3‡ 0-23 0-10
Range 0-190 0-12
esults are shown for all cases and controls and are stratiﬁed accord
versus no allergy).
Adjusted for severe (grade III–IV) acute GVHD and major ABO
Unadjusted P value.
Q indicates interquartile range.
26MX, it is not known whether they received daily or
ntermittent doses.
ISCUSSION
We conducted a retrospective matched case-con-
rol study of 155 patients who underwent HSCT at
he FHCRC in Seattle over 4 years to investigate
ematologic toxicity and the efﬁcacy of daily dapsone
s second-line PCP prophylaxis . A higher RBC and
latelet transfusion requirement was observed only in
atients who were switched from TMP-SMX to dap-
one after transplantation for reasons other than
MP-SMX allergy (mainly for poor marrow func-
ion). No differences in toxicity were observed among
atients who started their second-line PCP prophy-
axis before HSCT or after HSCT because of allergy
r intolerance to TMP-SMX. We found that daily
apsone had efﬁcacy similar to that of the standard
egimen with TMP-SMX in preventing PCP infec-
ions, although the sample size was too small to detect
mall differences. Patients who required alternative
rophylaxis seemed to have a trend toward a higher
ncidence of other infections typically prevented by
MP-SMX. The major concern about dapsone ad-
inistration is the possible development of hemolytic
eactions [13]. We decided to focus on the clinical
elevance of possible hemolytic events, which are ul-
imately the need for transfusions. A common reason
or using alternatives to TMP-SMX is neutropenia,
hich indicates poor marrow function of the host
ather than a drug effect. This could select a popula-
100 Days of Follow-Up among Patients Who Started Dapsone
Platelets
P Value Dapsone Controls P Value
116 232
.0003* 0.0 0.0 .02*
.0002† 0-79 0-19 .01†
0-1210 0-1231
48 96
.65* 0.0 0.0 .77*
.82† 0-49 0-34 .94†
0-326 0-1231
68 136
<.0001* 11.0 0.0 .003*
<.0001† 0-129 0-13 .002†
0-1210 0-886
he reason for dapsone second-line prophylaxis (TMP-SMX allergy
ch.its per
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Bion of patients with an independent higher transfu-
ion need. We therefore stratiﬁed our analysis accord-
ng to the reason why a second-line PCP prophylaxis
as started. We found that 83 patients were treated
ith dapsone because of allergy to TMP-SMX; 35
tarted before HSCT, and 48 received the drug only
fter HSCT. The number of transfusions in these 2
roups was similar to that observed in their corre-
ponding controls. However, patients who required
CP prophylaxis with daily dapsone for reasons other
han TMP-SMX allergy after HSCT had a signiﬁ-
antly higher need for transfusion compared with con-
rols. This suggests that there was preexisting poor
arrow function in these patients. Indeed, their trans-
usion need was higher than that of controls even in
he period between HSCT and the start of dapsone. In
ddition, the ANC and platelet count at the time
igure 2. Cumulative incidence curves of hemoglobin (HGB) decr
ransplantation (n  116) and their corresponding controls (n  23
o the reason for dapsone secondary prophylaxis: TMP-SMX allerg
ajor ABO mismatch, stem cell source, and age. *Unadjusted P vaement (8 g/dL) for patients who started dapsone for the ﬁrst time after
2). Results are shown for all cases and controls (A) and stratiﬁed according
y (B) versus no allergy (C). P values are adjusted for severe acute GVHD,rophylaxis started also suggested poor graft function. †
B&MTable 4. Infection Incidence at Any Time after HSCT for All Cases
nd Controls
Variable
Dapsone
(n  155)
Controls
(n  310)
aemophilus species 3 (2%)* 2 (1%)
oxoplasmosis 1 (1%) 0 (0%)
treptococcus pneumoniae 7 (5%)* 5 (2%)
ocardia species 1 (1%) 2 (1%)
CP 2 (1%) 0 (0%)
ny of the above (excluding PCP) 12 (8%) 9 (3%)†
he median time of infection (excluding PCP) incidence was 8.5
months after HSCT (range, 2-55 months) for cases and 6
months (range, 2-31 months) for controls.
Two independent infectious episodes of Haemophilus inﬂuenzae and
Streptococcus pneumoniae occurred in the same patient.P  .03.
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5ven if drug-associated toxicity had a probable role,
his was certainly not the only cause. The fact that
latelet requirements were also increased lends fur-
her support to this hypothesis, because dapsone is not
elieved to affect platelet number and function. Anal-
sis of laboratory parameters indicative of possible
emolysis, including hematocrit, haptoglobin, and
actate dehydrogenase, did not show signiﬁcant differ-
nces with the controls. The ﬁnding of a higher cu-
ulative incidence of hemoglobin decrements only in
atients who were not allergic to TMP-SMX also
upports the hypothesis of the underlying poor mar-
ow reserve as the main cause for the higher transfu-
ion requirement. It should be mentioned, however,
hat 12% of the cases had a reported clinical adverse
ffect associated with dapsone, and this led to drug
iscontinuation or temporary suspension in 10%.
Our ﬁndings on efﬁcacy are consistent with what
as been observed in HIV patients, in whom only
aily dapsone gave effective protection against pneu-
ocystis. It also conﬁrms the report by Vasconcelles
t al [13]. The low incidence of PCP infections in the
MP-SMX group was consistent with what we have
bserved in previous studies, where it was 0.37% [10].
he incidence in the dapsone group (1.3%) seemed
ower than that previously reported (7.2%) with inter-
ittent administration [10], suggesting that the daily
ose can make a difference. The development of PCP
ate after HSCT (7.5 and 11 months) in 2 patients
reated with dapsone was consistent with the new
rend observed with PCP infections after HSCT.
owever, the reasons for breakthrough are unknown.
oor adherence to the prophylactic regimen does not
eem to be a factor. Another hypothesis could be a
train of pneumocystis that is resistant to dapsone, a
efect in the intestinal absorption of the drug, or some
nknown pharmacologic interaction. A trend toward a
igher incidence of other encapsulated organisms and
ocardia was observed in patients who required sec-
nd-line PCP prophylaxis with dapsone compared
ith controls. Because dapsone does not provide suf-
cient coverage against encapsulated infections, addi-
ional antibacterial prophylaxis (eg, penicillin VK) is
ecommended according to Centers for Disease Con-
rol guidelines [25]. However, we could not obtain
ufﬁcient information about the adherence to penicil-
in-based antimicrobial prophylaxis. Of the 12 patients
ho developed such infections after HSCT, only 6
ere actually receiving second-line PCP prophylaxis
t the time the infectious event occurred, 2 still with
apsone, and 4 were switched to pentamidine because
f dapsone toxicity. Of the remaining patients, 5 had
een switched back to TMP-SMX, and 1 developed
he infection before he started the second-line pro-
hylaxis. Nevertheless, the trend toward a higher in-
idence of other infections emphasizes the need for
dditional prophylaxis aimed at these organisms [25].
28We conclude that a prophylactic regimen of daily
apsone (50 mg twice daily) among patients who used
t because of TMP-SMX allergy is not associated with
higher toxicity or transfusion requirement compared
ith matched controls. Thus, it may be considered a
alid second-line agent. Signiﬁcantly increased hema-
ologic toxicity and need for transfusion support were
bserved in the group of patients who were switched
rom TMP-SMX to dapsone for reasons other than
llergy, mainly for poor marrow reserve. Our study
annot conclusively determine whether the increased
oxicity is due to preexisting poor graft function. It is
ossible that dapsone is more toxic in this setting;
owever, a randomized trial is needed to determine
hether the drug itself might have an etiologic role in
hese situations. Dapsone intolerance leading to drug
iscontinuation or temporary suspension occurred in
0% of patients. The efﬁcacy of daily dapsone in
reventing PCP infections after HSCT was conﬁrmed
o be similar to that observed in controls receiving
MP-SMX, but a trend toward more breakthrough
nfections of other microorganisms not covered by
apsone was observed. Overall, the daily regimen
eemed to be superior to intermittent dapsone, which
as shown to be ineffective in an earlier study [10].
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